BRAF and lung cancer: In order to elucidate the potential mechanisms underlying gefitinib resistance in our established lung cancer cells, Sanger sequencing was performed and the results showed that EGFR 19del was present in these resistant lung cancer cells while there were no EGFR T790M mutation and other mutation such as BRAF or PIK3CA (Supplementary Figure S1B).